Mermaid Bio GmbH Secures $1 Million in Pre-Seed Funding for Innovative Intrabody Discovery Platform

Mermaid Bio GmbH is thrilled to announce the successful completion of a significant funding round, raising an impressive €1 million to further advance its innovative research and development efforts. Specializing in the discovery and development of groundbreaking intrabodies—antibodies specifically designed to target intracellular proteins—Mermaid Bio is at the forefront of addressing critical unmet medical needs. With its proprietary platform that combines single-domain antibodies, or nanobodies, with cutting-edge drug delivery systems using mRNA/lipid nanoparticle (LNP) technology, the company is set to revolutionize how therapies are delivered and accessed at a cellular level. This recent funding infusion will enable Mermaid Bio to accelerate its ongoing pipeline projects and enhance its capabilities in creating transformative therapeutics for diseases that currently lack effective treatments. The team is dedicated to harnessing these advanced technologies to unlock the potential of intrabodies, ultimately leading to more effective and tailored treatment options for patients. With the support of this funding, Mermaid Bio is poised to make significant strides in the biopharmaceutical arena, advancing towards clinical trials and unveiling new horizons in disease treatment. Investors and stakeholders alike recognize the importance of supporting innovative approaches in biotech, particularly in areas where conventional methodologies have fallen short. Mermaid Bio is committed to its mission and looks forward to deploying these resources to unlock the full potential of its revolutionary platform. As the company forges ahead, it remains dedicated to its vision of transforming patient care through science and innovation.